Home Industry Reports Custom Research Blogs About Us Contact us

Transthyretin Amyloidosis Treatment Market Size & Share, By Type (ATTR-CM, ATTR-PN), Disease Type (Hereditary, Wild Type), Drug Type (Tafamidis, Patisiran), Route of Administration (Oral, Parenteral), Distribution Channel (Hospital Pharmacy, Retail Drug Store), Regional Forecast, Industry Players, Growth Statistics Report 2024-2032

Report ID: FBI 3053


Published Date: May-2024


Format : PDF, Excel

Market Outlook:

Transthyretin Amyloidosis Treatment Market size crossed USD 6.08 Billion in 2023 and is poised to reach USD 11.76 Billion by 2032, observing around 7.8% CAGR between 2024 and 2032.

Base Year Value (2023)

USD 6.08 Billion

19-23 x.x %
24-32 x.x %

CAGR (2024-2032)


19-23 x.x %
24-32 x.x %

Forecast Year Value (2032)

USD 11.76 Billion

19-23 x.x %
24-32 x.x %
Transthyretin Amyloidosis Treatment Market

Historical Data Period


Transthyretin Amyloidosis Treatment Market

Largest Region

North America

Transthyretin Amyloidosis Treatment Market

Forecast Period


Get more details on this report -

Market Dynamics:

Growth Drivers & Opportunity:

1. Increasing prevalence of transthyretin amyloidosis: The growing prevalence of transthyretin amyloidosis is a major growth driver for the treatment market. This rare genetic disease is being increasingly diagnosed, leading to a greater demand for effective treatment options.

2. Advancements in treatment options: The development of novel therapies and treatment options for transthyretin amyloidosis is driving market growth. New drug approvals and innovative treatment approaches are expanding the market and providing more options for patients.

3. Rising awareness and screening of the disease: Increased awareness and screening programs for transthyretin amyloidosis are contributing to market growth. As more patients are diagnosed early, the demand for treatment is expected to rise, driving market expansion.

4. Growing research and development activities: The increasing investment in research and development activities for transthyretin amyloidosis treatment is another major growth driver. Ongoing clinical trials and studies focused on developing new therapeutic options are expected to positively impact the market.

Report Scope

Report CoverageDetails
Segments CoveredType, Disease Type, Drug Type, Route Of Administration, Distribution Channel
Regions Covered• North America (United States, Canada, Mexico) • Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe) • Asia Pacific (China, Japan, South Korea, Singapore, India, Australia, Rest of APAC) • Latin America (Argentina, Brazil, Rest of South America) • Middle East & Africa (GCC, South Africa, Rest of MEA)
Company ProfiledAcrotech Biopharma, LLC, Alnylam Pharmaceuticals, AstraZeneca PLC, Astellas Pharma, BridgeBio Pharma, Bristol-Myers Squibb Company, Ionis Pharmaceuticals, Johnson & Johnson, Prothena Biosciences Limited, Pfizer, SOM Innovation Biotech, S.L.

Unlock insights tailored to your business with our bespoke market research solutions - Click to get your customized report now!

Industry Restraints:

1. High treatment costs: The high cost of treatment for transthyretin amyloidosis is a significant restraint for the market. Expensive therapies can limit access for patients and pose a barrier to market growth.

2. Limited patient pool: The relatively small patient population for transthyretin amyloidosis presents a challenge for market expansion. The limited number of eligible patients can impact the adoption and utilization of treatment options.

3. Regulatory challenges: Regulatory hurdles and the complex nature of orphan drug approvals can also act as restraints for the market. The process of gaining regulatory approval for new treatments can be lengthy and challenging, impacting market growth.

In summary, while the increasing prevalence and awareness of transthyretin amyloidosis, as well as advancements in treatment options, are driving market growth, challenges such as high treatment costs, limited patient pool, and regulatory hurdles act as restraints for the transthyretin amyloidosis treatment market.

Regional Forecast:

Transthyretin Amyloidosis Treatment Market

Largest Region

North America

USD 38.73 Million in 2023

Get more details on this report -

North America (U.S., Canada):

Transthyretin Amyloidosis Treatment Market in North America is expected to show significant growth due to the presence of key players such as Pfizer Inc., Alnylam Pharmaceuticals, and Ionis Pharmaceuticals. The high prevalence of transthyretin amyloidosis in this region, along with the availability of advanced healthcare infrastructure and increased investment in research and development, are contributing to market growth. Additionally, favorable government initiatives and reimbursement policies are further boosting the market in North America.

Asia Pacific (China, Japan, South Korea):

In Asia Pacific, the transthyretin amyloidosis treatment market is projected to witness rapid growth owing to the increasing incidence of the disease and rising awareness about available treatment options. Countries such as China, Japan, and South Korea have a large patient pool, and the presence of emerging biopharmaceutical companies is driving market growth. Moreover, favorable government policies and increasing healthcare expenditure are expected to further propel the market in this region.

Europe (United Kingdom, Germany, France):

The transthyretin amyloidosis treatment market in Europe is anticipated to experience steady growth due to the presence of established healthcare infrastructure and a high prevalence of transthyretin amyloidosis in countries such as the United Kingdom, Germany, and France. The region also has a strong focus on research and development activities, which is leading to the introduction of novel treatment options. Additionally, collaborations between pharmaceutical companies and research institutions are contributing to the overall market growth in Europe.

Report Coverage & Deliverables

Historical Statistics Growth Forecasts Latest Trends & Innovations Market Segmentation Regional Opportunities Competitive Landscape
Transthyretin Amyloidosis Treatment Market
Transthyretin Amyloidosis Treatment Market

Segmentation Analysis:


In terms of segmentation, the global transthyretin amyloidosis treatment market is analyzed on the basis of Type, Disease Type, Drug Type, Route Of Administration, Distribution Channel.

Transthyretin Amyloidosis Treatment Market


The type segment in the transthyretin amyloidosis treatment market refers to the different forms of the condition that are treated. This includes hereditary transthyretin amyloidosis (hATTR) and wild type transthyretin amyloidosis (wtATTR). Hereditary transthyretin amyloidosis is caused by genetic mutations that affect the production of transthyretin protein, while wild type transthyretin amyloidosis occurs in individuals who do not have a genetic mutation but still experience the detrimental effects of transthyretin amyloidosis.

Disease Type:

The disease type segment in the transthyretin amyloidosis treatment market encompasses the specific organs and systems affected by the condition. Transthyretin amyloidosis primarily affects the nervous system and the heart, leading to various neurological and cardiac symptoms. Understanding the specific disease type is crucial in determining the appropriate treatment approach and management of symptoms for patients with transthyretin amyloidosis.

Drug Type:

The drug type segment in the transthyretin amyloidosis treatment market includes the different categories of pharmaceutical agents that are used to manage the condition. This encompasses the use of gene-silencing therapies, stabilizers of transthyretin tetramers, and monoclonal antibodies that target abnormal transthyretin deposits. These drug types aim to alleviate the symptoms of transthyretin amyloidosis and slow down the progression of the disease by addressing the underlying pathological mechanisms.

Route Of Administration:

The route of administration segment in the transthyretin amyloidosis treatment market denotes the various methods by which medications are delivered to patients. This includes oral administration, subcutaneous injection, and intravenous infusion. The choice of route of administration is determined by the specific drug type, patient characteristics, and therapeutic considerations, with the goal of ensuring effective delivery and optimal patient adherence to treatment regimens.

Distribution Channel:

The distribution channel segment in the transthyretin amyloidosis treatment market encompasses the various channels through which pharmaceutical products and medical devices are made available to patients. This includes hospital pharmacies, retail pharmacies, and online pharmacies, as well as specialty clinics and healthcare facilities. The selection of the appropriate distribution channel for transthyretin amyloidosis treatments is crucial in ensuring accessibility and availability for patients in need of these specialized therapies.

Get more details on this report -

Competitive Landscape:

The competitive landscape in the Transthyretin Amyloidosis Treatment Market is characterized by intense rivalry among key players, as they strive to gain a larger share of the market through various strategies such as product launches, collaborations, mergers, and acquisitions. With the rising prevalence of transthyretin amyloidosis and the increasing demand for effective treatment options, companies are focusing on developing innovative therapies and expanding their reach across different regions. Additionally, the growing investment in research and development activities is contributing to the competitiveness of the market, as companies aim to bring breakthrough treatments to the market. The top 10 companies operating in the Transthyretin Amyloidosis Treatment Market across the world include Pfizer Inc., Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Akcea Therapeutics, Inc., Eidos Therapeutics, FoldRx Pharmaceuticals, GlaxoSmithKline plc, Prothena Corporation plc, Bayer AG, and Caelum Biosciences, Inc. These companies are at the forefront of driving advancements in TTR amyloidosis treatment and are continuously striving to address the unmet needs of patients globally.

Top Market Players:

1. Pfizer Inc.

2. Alnylam Pharmaceuticals, Inc.

3. Ionis Pharmaceuticals

4. Akcea Therapeutics, Inc.

5. Eidos Therapeutics

6. FoldRx Pharmaceuticals

7. GlaxoSmithKline plc

8. Prothena Corporation plc

9. Bayer AG

10. Caelum Biosciences, Inc.

Our Clients

Why Choose Us

Specialized Expertise: Our team comprises industry experts with a deep understanding of your market segment. We bring specialized knowledge and experience that ensures our research and consulting services are tailored to your unique needs.

Customized Solutions: We understand that every client is different. That's why we offer customized research and consulting solutions designed specifically to address your challenges and capitalize on opportunities within your industry.

Proven Results: With a track record of successful projects and satisfied clients, we have demonstrated our ability to deliver tangible results. Our case studies and testimonials speak to our effectiveness in helping clients achieve their goals.

Cutting-Edge Methodologies: We leverage the latest methodologies and technologies to gather insights and drive informed decision-making. Our innovative approach ensures that you stay ahead of the curve and gain a competitive edge in your market.

Client-Centric Approach: Your satisfaction is our top priority. We prioritize open communication, responsiveness, and transparency to ensure that we not only meet but exceed your expectations at every stage of the engagement.

Continuous Innovation: We are committed to continuous improvement and staying at the forefront of our industry. Through ongoing learning, professional development, and investment in new technologies, we ensure that our services are always evolving to meet your evolving needs.

Value for Money: Our competitive pricing and flexible engagement models ensure that you get maximum value for your investment. We are committed to delivering high-quality results that help you achieve a strong return on your investment.

Select Licence Type

Single User

US$ 4250

Multi User

US$ 5050

Corporate User

US$ 6150

Transthyretin Amyloidosis Treatment Market Size & ...

RD Code : 24